Citations

Mayo Clinic

Clear

1479 citation(s) found for "Ma, Khan".

Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI)
Kiely, David G. , Levin, David L. , Ivy, D. Dunbar , Bwika, Jumaa, Lordan, Jim , Mazurek, Jeremy A. , Moledina, Shahin , Olschewski, Horst , Peacock, Andrew J. , Puri, G. D., Rahaghi, Farbod N. , Schäfer, Michal , Screaton, Nicholas, Noordegraaf, Anton Vonk , Vandepool, Rebecca, Wort, Stephen J. , Zhao, Lan , Wild, Jim M. , Vogel‐Claussen, Jens , Swift, Andrew J. , Vanderpool, Rebecca , Levin, David, Olschewski, Horst , Vonk Noordegraaf, Anton , Vanderpool, Rebecca R , Wild, Jim M , Hassoun, Paul M. , Jone, Pei-Ni , Kawut, Steven M. , Lungu, Angela , Schiebler, Mark , Tawhai, Merryn Howatson , Beek, Edwin J.R. van , Kiely, David , Vogel-Claussen, Jens

Pulmonary Circulation | March 18, 2019 | Volume: 9 | Issue: 3 | Pages: 1-32

10.1177/2045894019841990 | PMID 30880632 Get It

Pulmonary hypertension (PH) is highly heterogeneous and despite treatment advances it remains a life‐shortening condition. There have been significant advances in imaging technologies, but despite evidence of their potential clinical utility, practice remains variable, dependent in part on imaging availability and expertise. This statement summarizes current and emerging imaging modalities and their potential role in the diagnosis and assessment of suspected PH. It also includes a review of commonly encountered clinical and radiological scenarios, and imaging and modeling‐based biomarkers. An expert panel was formed including clinicians, radiologists, imaging scientists, and computational modelers. Section editors generated a series of summary statements based on a review of the literature and professional experience and, following consensus review, a diagnostic algorithm and 55 statements were agreed. The diagnostic algorithm and summary statements emphasize the key role and added value of imaging in the diagnosis and assessment of PH and highlight areas requiring further research.
Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.
Chanan‐Khan, Asher , Fraser, Graeme , Silva, Rodrigo Santucci, Pylypenko, Halyna, Janssens, Ann , Pristupa, Alexander , Mayer, Jiří , Dilhuydy, Marie‐Sarah, Loscertales, Javier, Avigdor, Abraham, Rule, Simon , Sun, Steven , Mahler, Michelle, Salman, Mariya, Howes, Angela, Cramer, Paula , Demırkan, Fatih , Grosicki, Sebastian , Bartlett, Nancy L. , Hallek, Michael

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: LBA7005-LBA7005

10.1200/jco.2015.33.15_suppl.lba7005 Get It

Apalutamide (APA) or enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (CRPC): A systematic review and network meta-analysis of randomized clinical trials (RCTs).
Bhattacharjee, Sandipan , Malik, Saad Ullah , Ho, Thanh P. , Sipra, Qurat Ul Ain Riaz , Farooq, Muhammad Zain, Riaz, Irbaz Bin , Khan, Safi U. , Murad, M. Hassan , Kohli, Manish

Journal of Clinical Oncology | March 7, 2019 | Volume: 37 | Issue: 7_suppl | Pages: 263-263

10.1200/jco.2019.37.7_suppl.263 Get It

263 Background: In non-metastatic CRPC with short PSA doubling time, APA or ENZA with ADT have shown to slow development of metastasis. We performed an indirect comparison of APA and ENZA clinical effectiveness (efficacy and side effects) using network meta-analysis. Methods: A search of Medline, Embase, Cochrane Library, and Cochrane Central Register of Controlled Trials was performed to identify relevant RCTs. Collected data included hazard ratio (HR) and confidence interval (CI) for primary outcome of median time to metastasis free survival (MFS) and secondary outcomes of median time to overall survival (OS), PSA progression, initiation of cytotoxic therapy and number of adverse events (AE) in each study arm. Risk for bias was assessed using the Cochrane Collaboration’s tool. We used a fixed effects model using Bayesian approach to generate pooled estimates. Results: Two randomized trials (n=2608) were analyzed. SPARTAN trial compared APA plus ADT to ADT alone and PROSPER compared ENZA plus ADT to ADT alone. Risk of bias was low. There were no statistically significant differences between APA and ENZA in MFS, OS, median time to PSA progression and initiation of cytotoxic therapy. The MFS endpoint hazard ratio (HR) was 0.97 (95% CI 0.73-1.28) for comparing the two drugs. APA had fewer reports of hypertension (HR 0.54, 95% CI 0.31–0.91) compared to enzalutamide. However, no significant differences were observed in other AEs including grade 3 or higher AE, serious AE, AE leading to death or trial discontinuation. Common AEs (nausea, diarrhea, fall, dizziness, arthralgia, weight loss) and AEs of special interests (mental impairment disorders, seizures) were also comparable between APA and ENZA. Conclusions: In non-metastatic CRPC with short PSA doubling time, APA and ENZA showed similar time to metastasis free survival. APA was associated with lower incidence of hypertension than ENZA; otherwise, side effect profile was similar. Given similar efficacy and risk profile demonstrated in this study, clinical decision making should depend on other factors such as cost and availability.
Impact of access to NCI/NCCN-designated cancer centers (CC) on overall survival (OS) in multiple myeloma (MM) patients (pts).
Advani, Pooja , Ghosh, Radhika , Swaika, Abhisek, Gupta, Deepansh, Foran, James M. , Colón‐Otero, Gerardo , Chanan‐Khan, Asher , Yang, Dongyun , Gupta, Deepansh, Roy, Vivek , Ailawadhi, Sikander

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e17570-e17570

10.1200/jco.2015.33.15_suppl.e17570 Get It

Aspirin for primary prevention of cardiovascular outcomes in diabetes mellitus: An updated systematic review and meta-analysis
Asad, Zain Ul Abideen , Talluri, Swapna, Khan, Muhammad Shahzeb , Lone, Ahmad Naeem , Mookadam, Farouk , Asad, Zain Ul Abideen , Khan, Safi U. , Khan, Muhammad U. , Ali, Farman, Krasuski, Richard A. , Kaluski, Edo

European Journal of Preventive Cardiology | January 31, 2019 | Volume: 27 | Issue: 19 | Pages: 2034-2041

10.1177/2047487319825510 | PMID 30700151 Get It

Background The safety and efficacy of aspirin for the primary prevention of cardiovascular disease in patients with diabetes mellitus remains controversial. Design A meta-analysis to investigate the effects of aspirin for the prevention of cardiovascular disease in diabetes mellitus. Methods Ten randomized controlled trials were selected using MEDLINE, EMBASE and CENTRAL databases until 27 September 2018. Risk ratios (RRs) with 95% confidence intervals (CIs) and risk differences (RDs) reported as incident events per 1000 person-years were calculated. Results In 33,679 patients, aspirin did not significantly reduce the risk of major adverse cardiovascular outcomes (RR 0.93, 95% CI 0.87–1.00, P = 0.06; RD −0.68 incident cases per 1000 person-years (95% CI −1.54, 0.17)), cardiovascular mortality (RR 0.95, 95% CI 0.83–1.09, P = 0.49; RD 0.11 incident cases per 1000 person-years (95% CI −0.80, 1.02)), myocardial infarction (RR 0.91, 95% CI 0.75–1.11, P = 0.36; RD −0.66 incident cases per 1000 person-years (95% CI −2.07, 0.75)), or stroke (RR 0.91, 95% C, 0.76–1.10, P = 0.33; RD −0.55 incident cases per 1000 person-years (95% CI −1.57, 0.47)). There was a significantly higher risk of total bleeding associated with aspirin (RR 1.29, 95% CI 1.07–1.55, P = 0.01; RD 1.49 incident cases per 1000 person-years (95% CI 0.36, 2.61)). Conclusion The use of aspirin for primary prevention of cardiovascular disease in patients with diabetes mellitus increases the risk of total bleeding without reducing the risk of major adverse cardiovascular outcomes.
Abstract TMP96: Carotid Plaque Characteristics Correlated to Baseline Vascular Risk Factors in a Large Randomized Trial: Results from CREST-2
Lal, Brajesh K. , Chrencik, Matthew T. , Khan, Amir , Jones, Michael , Sternbergh, Charles, Rapp, Joseph H., Mukherjee, Dipankar , Henke, Peter K. , Yokemick, John, Moore, Wesley S. , Voeks, Jenifer H. , Brott, Thomas G. , Huston, John , Sikdar, Siddhartha , Howard, George , Meschia, James F.

Stroke | January 30, 2019 | Volume: 50 | Issue: Suppl_1 | Pages: No page available

10.1161/str.50.suppl_1.tmp96 Get It

Objectives: Assessment of carotid disease is most commonly performed with duplex ultrasonography (DUS). Measures of plaque area and tissue composition from DUS images may identify patients at risk for future neurologic events, and may assess the effects of vascular risk-factor modification (by measuring change in plaque area and/or tissue constituents). We quantified plaque area and tissue constituents from DUS images of CREST-2 participants at baseline and correlated them with their baseline vascular risk factors. Methods: CREST-2 consists of two multicenter, randomized trials in patients with asymptomatic ≥70% carotid stenosis comparing intensive medical management (IMM) plus endarterectomy or stenting vs IMM alone. Baseline B-mode DUS images from 500 patients underwent manual plaque outlining and automatic pixel brightness assessment. Plaque area, grayscale median (GSM), Gray-Weale score for heterogeneity, and areas for intraplaque hemorrhage and lipid were the output parameters. We computed the parameter estimates (95% confidence intervals) for baseline patient characteristics (age, sex, race, diabetes, smoking, BMI, blood pressure and LDL levels) versus plaque characteristics. Results: High-risk plaque features (larger plaque area, lower GSM , lower Gray-Weale scores, or larger areas of hemorrhage and lipid) were present in older patients, males, and those with elevated diastolic blood pressure and LDL levels (Table). Conclusions: In a randomized trial of asymptomatic patients with high-grade carotid stenosis, DUS-based computation of plaque geometry and tissue composition is feasible. Elevated diastolic blood pressure and LDL levels at baseline are associated with high-risk plaque characteristics. These novel findings identify potentially modifiable targets for aggressive treatment to reduce stroke-risk in patients with carotid stenosis.
Workforce, Workload, and Burnout Among Intensivists and Advanced Practice Providers: A Narrative Review
Kvetan, Vladimír, Farmer, Joseph C. , Sessler, Curtis N., Christman, John W. , D’Agostino, Rhonda, Gregg, Sara, Khan, Roozehra, Kapu, April N. , Masur, Henry , Mehta, Gargi, Moore, Jason E. , Oropello, John M., Price, Kristen , Hite, R. Duncan , Farmer, J Christopher, Diaz-Gomez, Jose, Pastores, Stephen M. , Coopersmith, Craig M , Díaz‐Gómez, José L.

Critical Care Medicine | January 26, 2019 | Volume: 47 | Issue: 4 | Pages: 550-557

10.1097/ccm.0000000000003637 | PMID 30688716 Get It

Objectives: To assess—by literature review and expert consensus—workforce, workload, and burnout considerations among intensivists and advanced practice providers. Design: Data were synthesized from monthly expert consensus and literature review. Setting: Workforce and Workload section workgroup of the Academic Leaders in Critical Care Medicine Task Force. Measurements and Main Results: Multidisciplinary care teams led by intensivists are an essential component of critical care delivery. Advanced practice providers (nurse practitioners and physician assistants) are progressively being integrated into ICU practice models. The ever-increasing number of patients with complex, life-threatening diseases, concentration of ICU beds in few centralized hospitals, expansion of specialty ICU services, and desire for 24/7 availability have contributed to growing intensivist staffing concerns. Such staffing challenges may negatively impact practitioner wellness, team perception of care quality, time available for teaching, and length of stay when the patient to intensivist ratio is greater than or equal to 15. Enhanced team communication and reduction of practice variation are important factors for improved patient outcomes. A diverse workforce adds value and enrichment to the overall work environment. Formal succession planning for ICU leaders is crucial to the success of critical care organizations. Implementation of a continuous 24/7 ICU coverage care model in high-acuity, high-volume centers should be based on patient-centered outcomes. High levels of burnout syndrome are common among intensivists. Prospective analyses of interventions to decrease burnout within the ICU setting are limited. However, organizational interventions are felt to be more effective than those directed at individuals. Conclusions: Critical care workforce and staffing models are myriad and based on several factors including local culture and resources, ICU organization, and strategies to reduce burden on the ICU provider workforce. Prospective studies to assess and avoid the burnout syndrome among intensivists and advanced practice providers are needed.
Factors Associated With Return-to-Work Following Cervical Spine Surgery in Non-Worker's Compensation Setting
Kim, Elliott J., Chotai, Silky , Wick, Joseph B. , Khan, Inamullah , Sivaganesan, Ahilan, Bydon, Mohamad , Archer, Kristin R. , Devin, Clinton J. , Kim, Elliott J.

Spine | January 19, 2019 | Volume: 44 | Issue: 13 | Pages: 903-907

10.1097/brs.0000000000002978 | PMID 31205165 Get It

Study Design. This study retrospectively analyzes prospectively collected data. Objective. Here in this study we aim to determine the factors which impact a patient's ability to return to work (RTW) in the setting of cervical spine surgery in patients without worker's compensation status. Summary of Background Data. Surgical management of degenerative cervical disease has proven cost-effectiveness and shown significant improvement in quality of life. However, the ability to RTW is an important clinical outcome for preoperatively employed patients. Methods. All adult patients undergoing elective surgery for cervical degenerative disease at our institution are enrolled in a prospective, web-based registry. A multivariable Cox proportional hazards regression model was built for time to RTW. The variables included in the model were age, sex, smoking status, occupation type, number of levels operated on, ASA grade, body mass index, history of diabetes, history of coronary artery disease (CAD), history of chronic obstructive pulmonary disease (COPD), anxiety, depression, myelopathy at presentation, duration of symptoms more than 12 months, diagnosis, type of surgery performed, and preoperative Neck Disability Index, EuroQol Five Dimensions, and Numeric Rating Scale pain scores for neck pain and arm pain scores. Results. Of the total 324 patients with complete 3-month follow-up data 83% (n = 269) returned to work following surgery. The median time to RTW was 35 days (range, 2–90 d). Patients with a labor-intensive occupation, higher ASA grade, history of CAD, and history of COPD were less likely to RTW. The likelihood of RTW was lower in patients with a diagnosis of disc herniation compared with cervical stenosis, patients undergoing cervical corpectomy compared laminectomy and fusion and patient with longer operative time. Conclusion. Our study identifies the various factors associated with a lower likelihood of RTW at 3 months after cervical spine surgery in the non-worker's compensation setting. This information provides expectations for the patient and employer when undergoing cervical spine surgery. Level of Evidence: 3
Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia
Khurana, Sharad , Alegria, Victoria R., Aulakh, Sonikpreet , Ailawadhi, Meghna, Singh, Anshika , Chanan‐Khan, Asher , Ahmed, Salman , Chanan-Khan, Asher, Ahmed, Salman , Ailawadhi, Sikander

SAGE Open Medical Case Reports | January 16, 2019 | Volume: 7 | Issue: No issue available | Pages: No page available

10.1177/2050313x18823917 | PMID 30728976 Get It

Obinutuzumab is used for the treatment of chronic lymphocytic leukemia. So far there are no data of using this for retreatment in patients who have received it previously. We introduced obinutuzumab for the retreatment in a chronic lymphocytic leukemia patient, who had first achieved partial remission with it and eventually relapsed over a course of 2.5 years. After retreatment with single-agent obinutuzumab, the patient achieved a partial remission again within one cycle and continues to maintain the response status. This case is a platform for considering obinutuzumab as a viable option for retreatment of chronic lymphocytic leukemia patients who have received it before, similar to the pattern of use for other anti-CD20 monoclonal antibodies in this disease, including rituximab.
E1A06: A phase III trial comparing melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed multiple myeloma (MM).
Stewart, A. Keith, Jacobus, Susanna , Weiss, Matthias , Chanan‐Khan, Asher , Fonseca, Rafaël , Callander, Natalie S. , Rajkumar, S. Vincent

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8511-8511

10.1200/jco.2014.32.15_suppl.8511 Get It